Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Drops By 62.4%

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 94,200 shares, a drop of 62.4% from the February 28th total of 250,300 shares. Approximately 4.2% of the company’s shares are sold short. Based on an average trading volume of 852,200 shares, the short-interest ratio is presently 0.1 days.

GT Biopharma Stock Up 4.3 %

NASDAQ:GTBP traded up $0.10 during trading hours on Friday, reaching $2.40. The company had a trading volume of 15,611 shares, compared to its average volume of 581,285. GT Biopharma has a twelve month low of $1.72 and a twelve month high of $10.66. The firm has a market cap of $6.09 million, a price-to-earnings ratio of -0.34 and a beta of 0.59. The business’s 50-day simple moving average is $2.29 and its two-hundred day simple moving average is $2.50.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Roth Mkm began coverage on GT Biopharma in a research report on Monday, December 2nd. They set a “buy” rating and a $11.00 target price on the stock. Roth Capital raised GT Biopharma to a “strong-buy” rating in a research note on Monday, December 2nd.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.